The effect of l-carnitine and erythropoietin on anemia in hemodialysis patients

Comparison of the effect of erythropoietin and placebo with the combination of l-carnitine and erythropoietin on anemia in hemodialysis patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200225046620N1

Enrollment

Registered

2020-03-24

Start date

2020-02-20

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia. Anemia in chronic kidney disease

Interventions

Intervention 1: Intervention group 1: receiving erythropietin 2000 IU three times a week subcutaneously for three months plus l-carnitine placebo daily orally for three months. Intervention 2: Interve

Eligibility

Sex/Gender

All

Age

No minimum to 30 Years

Inclusion criteria

Inclusion criteria: Age of less than 30 years Having a history of at least 6 month of dialysis

Exclusion criteria

Exclusion criteria: Having an active infectious or inflammatory disease

Design outcomes

Primary

Measure	Time frame
Serum hemoglobin level. Timepoint: Before study, three month after taking drugs. Method of measurement: By measuring complete blood count in laboratory.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Attaran Kakhk

Zahedan University of Medical Sciences

ayubabedi48@gmail.com+98 54 3329 5715

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026